Related Experiment Video
Updated: Mar 8, 2026

High-throughput Detection Method for Influenza Virus
Published on: February 4, 2012
Microbiology Devices; Reclassification of Influenza Virus Antigen Detection Test Systems Intended for Use Directly
Abstract:
The Food and Drug Administration (FDA) is reclassifying antigen based rapid influenza virus antigen detection test systems intended to detect influenza virus directly from clinical specimens that are currently regulated as influenza virus serological reagents from class I into class II with special controls and into a new device classification regulation.
Insights
The Food and Drug Administration (FDA) is updating regulations for rapid influenza diagnostic tests. These antigen tests will move from Class I to Class II, requiring special controls for improved accuracy and patient safety.
Area of Science:
- Medical Diagnostics
- Regulatory Science
- Infectious Disease Testing
Background:
- Current regulation of antigen-based rapid influenza virus antigen detection test systems.
- Existing classification as influenza virus serological reagents.
- Need for updated regulatory pathways for diagnostic devices.
Purpose of the Study:
- To reclassify antigen-based rapid influenza virus antigen detection test systems.
- To establish a new device classification regulation for these tests.
- To implement special controls for enhanced regulatory oversight.
Main Methods:
- Review of existing regulatory classifications for diagnostic tests.
- Assessment of performance characteristics of rapid influenza antigen detection systems.
- Development of new regulatory framework incorporating special controls.
Main Results:
- Reclassification of rapid influenza antigen detection test systems from Class I to Class II.
- Introduction of a new device classification regulation.
- Establishment of specific special controls for these tests.
Conclusions:
- The reclassification aims to ensure the safety and effectiveness of rapid influenza diagnostic tests.
- Implementation of special controls will enhance the reliability of influenza virus detection.
- The new regulatory approach supports advancements in infectious disease diagnostics.

